Our investigational compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Clinical trials and regulatory approvals will be necessary to evaluate Phyto-N's safety and efficacy for potential therapeutic use. We are committed to rigorous scientific research and adherence to regulatory standards in exploring Phyto-N's potential to address these medical needs.